¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"specific death rate"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • national death index
    ±¹¹Î»ç¸ÁÁö¼ö
  • natural death
    ÀÚ¿¬»ç
  • prenatal death
    Ãâ»ýÀü»ç¸Á
  • programmed cell death
    ¼¼Æ÷¿¹Á¤»ç
  • somatic death
    °³Ã¼»ç¸Á, ü»ç
  • sudden cardiac death
    ±Þ¼º½ÉÀå»ç
  • sudden infant death syndrome
    ¿µ¾Æµ¹¿¬»çÁõÈıº
  • systemic death
    Àü½Å»ç¸Á
  • unusual death
    º¯»ç
  • underlying cause of death
    ¼±Çà»ç¸Á¿øÀÎ
  • violent death
    ¿ÜÀλç
  • donor-specific phage
    Á¦°øÀÚÆ¯ÀÌÆÄÁö, °ø¿©ÀÚÆ¯ÀÌÆÄÁö
  • granulocyte-specific antigen
    °ú¸³±¸Æ¯ÀÌÇ׿ø
  • group-specific
    ±ºÆ¯ÀÌ-
  • group-specific antigen
    ¹«¸®Æ¯ÀÌÇ׿ø, ±ºÆ¯ÀÌÇ׿ø
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • pregnancy rate
    Àӽŷü
  • prevalence rate
    À¯º´·ü
  • pulse rate
    ¸Æ¹Ú¼ö
  • relaxation rate
    À̿Ϸü
  • respiratory rate
    È£Èí¼öÈ£Èí·ü
  • response rate
    ¹ÝÀÀ·ü
  • survival rate
    »ýÁ¸·ü
  • tidal rate
    È£Èí¼ö
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • neonatal death
    ½Å»ý¾Æ»ç¸Á, ¿µ¾Æ»ç
  • prenatal death
    Ãâ»ýÀü»ç¸Á
  • programmed cell death
    ¼¼Æ÷¿¹Á¤»ç
  • sociological death
    »çȸÀûÁ×À½
  • somatic death
    °³Ã¼»ç¸Á
  • sudden cardiac death
    ±Þ¼º½ÉÀå»ç
  • systemic death
    Àü½Å»ç
  • thermal death
    ¿­»ç, ¿­»ç¸ê
  • unusual death
    º¯»ç
  • violent death
    ¿ÜÀλç
  • fetal death ratio
    žƻç¸Áºñ
  • infant death statistics
    ¿µ¾Æ»ç¸ÁÅë°è
  • national death index
    ±¹¹Î»ç¸ÁÁö¼ö
  • sudden infant death syndrome
    ¿µ¾Æ±Þ»çÁõÈıº
  • sudden manhood death syndrome
    ûÀå³â±Þ»çÁõÈıº
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • Westergren sedimentation rate
    ¿þ½ºÅͱ׷»Ä§°­¼Óµµ
  • absorbed dose rate
    Èí¼ö¼±·®À²
  • air kerma-rate constant
    °ø±âÄ¿¸¶À²»ó¼ö
  • alveolar ventilation rate
    ÆóÆ÷ȯ±âºñ(¡­üµÑ¨Ýï)
  • arterial perfusion rate
    µ¿¸Æ°ü·ùÀ²
  • fractional fibrinogen catabolic rate
    ºÐȹº° ¼¶À¯¼Ò¿ø ´ë»çÀ².
  • frame rate
    È­¸éÀ²
  • frame rate
    È­¸é ¹ß»ýÀ² (ûþØü Û¡ßæëÒ)
  • general fertility rate
    ÀϹÝÃâ»êÀ².
  • general fertility rate
    ÀϹÝÃâ»êÀ².
  • glomerular filtration rate
    »ç±¸Ã¼ ¿©°úÀ²
  • glomerular filtration rate
    »ç±¸Ã¼¿©°úÀ²
  • glomerular filtration rate =GFR
    »ç±¸Ã¼¿©°úÀ²(¡­ÕëΦëÏ).
  • glomerular filtration rate =GFR
    »ç±¸Ã¼¿©°úÀ².
  • gross reproduction rate
    ÃÑÀç»ý»êÀ².
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • crib death
    ¿ä¶÷»ç
  • crib death
    ħ´ëµ¹¿¬»ç(öÖÓæÔÍæÔÞÝ)
  • crib death
    ¿µ¾Æµ¹¿¬»ç, ħ´ë»ç(öÖÓæÞÝ).
  • death certificates
    »ç¸ÁÁø´Ü¼­, ½Ãü°Ë¾È¼­
  • death instinct
    Á×À½º»´É(ÜâÒö)
  • death phase
    »ç¸ê±â
  • death point, thermal
    ¿­»ç¸ê¿Âµµ
  • death time, thermal
    ¿­»ç¸ê½Ã°£
  • death, cellular (molecular)
    ¼¼Æ÷»ç¸Á, ¼¼Æ÷»ç
  • death, organ
    Àå±â»ç¸Á
  • death, somatic
    °³Ã¼»ç¸Á
  • early fetal death
    Á¶±âžƻç¸Á.
  • electric death
    °¨Àü»ç.
  • fetal death
    žƻç¸Á(÷Ãä®ÞÝØÌ).
  • genetic death
    À¯Àü»ç(¡­ÞÝ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • specific rotation
    ºñ¼±±¤µµ(ÝïàÁÎÃÓø)
  • specific rotatory power
    ºñ¼±±¤·Â(ÝïàÁÎÃÕô)
  • specific substrate concentration
    ƯÀÌ ±âÁú³óµµ(÷åì¶ÐñòõÒØÓø)
  • specific viscosity
    ºñÁ¡µµ(ÝïïÄÓø)
  • specific volumne
    ºñ¿ëÀû(Ýïé»îÝ)
  • tissue-specific enzyme
    Á¶Á÷ ƯÀÌ È¿¼Ò (ðÚòÄ÷åì¶ý£áÈ)
  • tumor-specific transplantation antigen
    Á¾¾çƯÀÌ ÀÌ½Ä Ç׿ø(ðþåË÷åì¶ì¹ãÕù÷ê«)
  • type-specific antigen
    ÇüƯÀÌ Ç׿ø(úþ÷åì¶ù÷ê«)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
NDR neonatal death rate; normal detrusor reflex
RCDR relative corrected death rate
HBsAg/adr hepatitis B surface antigen manifesting group-specific determinant a and subtype-specific determinan...
LSP left sacroposterior [fetal position]; linguistic string project; liver-specific protein; lymphocyte-...
TS Takayasu syndrome; Tay-Sachs; temperature sensitivity; temperature, skin; temporal stem; tensile str...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
SDS Sudden Death Syndrome
SID Sudden Infant Death
SIDS Suddern Infant Death Syndrome
SUDS Sudden Unexplained Death Syndrome
SCD Sudden cardiac death
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • specific tender point site
    ƯÁ¤ ¾ÐÅëÁ¡
  • specific weight
    ºñÁß
  • tumor specific transplantation
    Á¾¾ç ƯÀ̼º À̽Ä
  • virus-specific surface antigen
    ¹ÙÀÌ·¯½º ƯÀ̼º Ç¥¸é Ç׿ø ¹ÙÀÌ·¯½º
  • absorptace rate
    Èí¼öÀ²
    ÀÎü¿¡ Á¶»çµÇ´Â ¹æ»ç¼±¿¡ ´ëÇØ ÀÎü¿¡ Èí¼öµÇ´Â ¹æ»ç¼± ¿¡³ÊÁöÀÇ ºñÀ².
  • absorption rate
    Èí¼öÀ²
    ÀÏÁ¤ ½Ã°£¿¡ »¡¾ÆµéÀÌ´Â ¼Óµµ¸¦ ³ªÅ¸³»´Â À².
  • attack rate
    ¹ßº´·ü, ÀÌȯÀ²
  • basal metabolic rate
    ±âÃÊ ´ë»çÀ²
    ½Ä»ç ÈÄ ÀÏÁ¤ ½Ã°£ÀÌ Áö³ª°í ³ª¼­ÀÇ ¾ÈÁ¤ »óÅ¿¡¼­ÀÇ »ê¼Ò ¼Òºñ ¼Óµµ.
  • cardiac rate
    ½É¹Ú ¼ö
    µ¿ÀǾî=heart rate.
  • caries incidence rate
    ¿ì½Ä¹ß»ýÀ²
    ÀÏÁ¤ÇÑ ±â°£¿¡ ¹ß»ýÇÏ´Â ¿ì½Ä ¹ß»ýÀ², ¨ç Æò±Õ ³â°£ ¿ì½Ä¹ß»ýÀ² =
  • case fatality rate
    Ä¡¸í·ü
  • conversion rate
    ÀüȯÀ²
  • D.E.F. rate
    µð.ÀÌ.¿¡ÇÁ
    Decayed Extractlion, FilledÀÇ ¾àÀÚ.
  • daily secretion rate
    ÀÏÀÏ ºÐºñ·®
  • diffusion rate
    È®»êÀ²
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
glycoprotein hormone-specific N-acetylgalactosamine transferase <enzyme> Transfers galnac to the terminal glcnac moieties of glcnac2man3glcnac2asn
Registry number: EC 2.4.1.-
Synonym: ghs-acgalnh2 transferase, glycoprotein hormone galnac transferase, glycoprotein hormone - n-acetylgalactosaminyltransferase
(26 Jun 1999)
retina-specific amine oxidase <enzyme> Genbank d88213
Registry number: EC 1.4.-
Synonym: rao enzyme, human
(26 Jun 1999)
Gomori's non-specific acid phosphatase stain <technique> A method in which formalin-fixed frozen sections are incubated in a substrate containing sodium beta-glycerophosphate and lead nitrate at pH 5.0; the insoluble lead phosphate produced is treated with ammonium sulfide to give a black lead sulfide.
(05 Mar 2000)
Gomori's non-specific alkaline phosphatase stain <technique> A calcium-cobalt sulfide method using frozen sections or cold acetone-or formalin-fixed paraffin sections, plus sodium beta-glycerophosphate as a substrate at pH 9.0 to 9.5 with Mg++ as activator; calcium ions precipitate the liberated phosphate, cobalt salt replaces the calcium phosphate, and ammonium sulfide converts the product to a black cobalt sulfide.
(05 Mar 2000)
group-specific protease <enzyme> A serine protease, obtained from rat small intestine, which preferentially inactivates the apo forms of certain pyridoxal phosphate requiring enzymes
Registry number: EC 3.4.21.-
(26 Jun 1999)
RNA, transfer, amino acid-specific A group of transfer rnas which are specific for carrying each one of the 20 amino acids to the ribosome in preparation for protein synthesis.
(12 Dec 1998)
poly A specific exoribonuclease <enzyme> Acts on 2' or 3'-linked oligoriboadenylates to liberate 5'-AMP
Registry number: EC 3.1.13.-
Synonym: 2',3'-exoribonuclease, 3'-exoribonuclease
(26 Jun 1999)
poly(A)-specific ribonuclease <enzyme> From vigna unguiculata seedlings; bifunctional enzyme responsible for both poly(a)-polymerizing and poly(a)-hydrolyzing activities; removes the poly(a) tail as the first step in degrading mRNA
Registry number: EC 3.1.13.4
Synonym: poly(a) nuclease, mRNA poly(a) nuclease, poly(a) ribonuclease (pan), pan2 protein
(26 Jun 1999)
myelencephalon-specific serine protease <enzyme> Specifically expressed in the nervous system; plays a role in normal homeostasis and response of spinal cord to injury.
Registry number: EC 3.4.21.-
Synonym: myelencephalon-specific protease, msp enzyme
(26 Jun 1999)
pregnancy-specific beta 1-glycoprotein A glycoprotein with the electrophoretic mobility of a beta-1 globulin. It is produced by the placental trophoblast and secreted into the maternal bloodstream during pregnancy. It can be detected 18 days after ovulation and its concentration in plasma rises steadily until, at the end of gestation, it reaches 200 mg/ml. It has been proposed as a measure of placental function for fertility control and is a candidate for an early pregnancy test.
(12 Dec 1998)
prenylated peptide-specific endoprotease <enzyme> Cleaves c-terminal tripeptide from prenylated protein having c-terminal sequence caax; race is rac and a-factor converting enzyme with same activity
Registry number: EC 3.4.14.-
Synonym: prenylated protein endoprotease, race enzyme, isoprenylated protein endopeptidase, isoprenylated protein endoprotease
(26 Jun 1999)
cytosol non-specific dipeptidase <enzyme> Also referred to as peptidase a (see synonym to penicillopepsin, EC 3.4.23.20)
Registry number: EC 3.4.13.-
Synonym: glycyl-l-leucine hydrolase, glycylleucine dipeptidase, gly-leu dipeptide peptidase, dipeptide hydrolase, glycyl-leucine dipeptidase
(26 Jun 1999)
cytotoxic T lymphocyte-specific serine protease <enzyme> Structural sequence given in first source
Registry number: EC 3.4.21.-
Synonym: cytotoxic t lymphocyte-specific serine protease ccp I, cytotoxic t lymphocyte specific serine protease ccp II, mast cell protease type II
(26 Jun 1999)
proline-specific dipeptidylcarboxypeptidase <enzyme> From streptomyces species; removes diproline form c-terminus of proline-containing peptides such as boc-pro-pro-pro-pro or leu-pro-pro-pro-pro-pro
Registry number: EC 3.4.15.-
Synonym: pro-dpp-carboxypeptidase
(26 Jun 1999)
prostate-specific antigen <tumour marker> A simple blood test used to detect prostate cancer in men. The test measures a specific antigen normally secreted by the prostate. If cancer is developing, the prostate secretes greater amounts of prostate-specific antigen. This test is recommended for men with an enlarged prostate and an increased risk of prostate cancer.
It is an enzyme that is produced by epithelial cells of both benign and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
It is a single chain 31 kilodalton glycoprotein with 240 amino acid residues and 4 carbohydrate side chains that is a kallikrein protease.
It is found in normal seminal fluid and produced by the prostatic epithelial cells.
Elevated levels in blood serum are associated with prostatic enlargement and prostatic adenocarcinoma, and this allows early detection of cancer in many cases. In about 70% of cases, the rise is due to a cancerous condition.
No large scale clinical studies have been completed to assess the impact of testing on survival from prostate cancer, and the medical and economic value of testing remain uncertain.
Acronym: PSA
Registry number: EC 3.4.21.77
(22 Sep 2002)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • heart rate
    ¸Æ¹Ú
  • monthly rate
    1°³¿ù ¿ä±Ý
  • rate
    ºñÀ²,À²,(º¹¼ö)¿ä±Ý,Æò°¡ÇÏ´Ù
  • ad rate
    ±¤°í·á
  • bank rate
    ¾îÀ½ÇÒÀÎÀ²;ÀºÇàÀϺ¯
  • birth rate
    Ãâ»êÀ²
  • call rate
    ÄÝ·ÐÀÇ ÀÌÀ²
  • card rate
    Ç¥ÁظÅü¿ä±Ý(½Å¹®»ç.¹æ¼Û±¹ µîÀÌ °øÇ¥ÇÑ ±¤°í Ç¥ÁØ ¿ä±ÝÇ¥)
  • carload rate
    È­Â÷ Àü¼¼ Ãë±Þ ¿îÀÓ·ü
  • centra rate
    Á߽ɽü¼(º¯µ¿ ½Ã¼¼Á¦ ÀÌÀüÀÇ °¢±¹ ȯÀÇ ¹Ì±¹ ´Þ·¯¿¡ ´ëÇÑ °øÁ¤ ȯÀ²)
  • charter rate
    Ưº° ¿ä±Ý(»õ ÀâÁöÀÇ Á¤±â ±¸µ¶ÀÚ.±¤°íÁÖ µîÀ» À§ÇÑ ÇÒÀÎ ¿ä±Ý)
  • church rate
    (±³±¸ÀÇ)±³È¸ À¯Áö¼¼
  • continuation rate
    ÀÌ¿ù ÀϺ¯
  • coupon rate
    ä±ÇÀÇ Ç¥¸é ÀÌÀÚÀ²
  • cross rate
    Å©·Î½º ·¹ÀÌÆ®;¿µ.¹Ì ȯ½Ã¼¼
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á